| Identification | Back Directory | [Name]
4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- | [CAS]
748120-89-0 | [Synonyms]
4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- | [Molecular Formula]
C21H30F3N3O7S | [MOL File]
748120-89-0.mol | [Molecular Weight]
525.54 |
| Hazard Information | Back Directory | [Uses]
SD-7300 (SC-81490) is an orally active inhibitor of MMP-2, MMP-9, and MMP-13 with Ki values ??of 0.03, 0.01, and 0.03 nM, respectively. SD-7300 can reduce the degradation of extracellular matrix by tumor cells, thereby inhibiting the invasion and metastasis of tumor cells. In addition, SD-7300 is also a dose-dependent inhibitor of mouse corneal angiogenesis and an inhibitor of interleukin-1-induced bovine cartilage degradation. SD-7300 can be used in breast cancer research[1]. | [IC 50]
MMP-2: 0.03 nM (Ki); MMP-9: 0.01 nM (Ki); MMP13: 0.03 nM (Ki) | [References]
[1] Winer, et al. "Inhibition of breast cancer metastasis by presurgical treatment with an oral matrix metalloproteinase inhibitor: a preclinical proof-of-principle study." Molecular cancer therapeutics 15.10 (2016): 2370-2377. DOI:10.1158/1535-7163.MCT-16-0194 |
|
|